Third Affiliated Hospital, Sun Yat-Sen University
zssy.com.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
130
Active
29
Phase 3
5
Total enrollment
104,522
Pipeline matrix
Showing 28 of 28 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| pegylated interferon-alfa | — | — | — | — | — | 1 | |
| Nucleoside Analogs | — | — | — | — | — | 1 | |
| Vitamin D3 | — | — | — | — | — | 1 | |
| Peginterferon Alfa-2B | — | — | — | — | 5 | ||
| methylprednisolone | — | — | — | — | 2 | ||
| Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody | — | — | — | — | — | 1 | |
| Hepatic Arterial Infusion Chemotherapy | — | — | — | — | — | 1 | |
| Adebrelimab | — | — | — | — | — | 1 | |
| Low-dose Bevacizumab | — | — | — | — | — | 1 | |
| MSC-EVs | — | — | — | — | 2 | ||
| Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours） | — | — | — | — | — | 1 | |
| Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours） | — | — | — | — | — | 1 | |
| Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours） | — | — | — | — | — | 1 | |
| Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（Multiple-treatment） | — | — | — | — | — | 1 | |
| Concentrated Growth Factors | — | — | — | — | — | 1 | |
| exosome | — | — | — | — | — | 1 | |
| standard comprehensive internal medical treatment, | — | — | — | — | — | 1 | |
| Tenofovir Disoproxil Fumarate | — | — | — | — | 7 | ||
| Entecavir | — | — | — | 5 | |||
| Tenofovir Alafenamide | — | — | — | — | — | 3 | |
| Entecavir or Tenofovir | — | — | — | — | 2 | ||
| Tenofovir alafenamide fumarate | — | — | — | — | — | 2 | |
| TACE-HAIC + Atezolizumab + Low-dose Bevacizumab | — | — | — | — | — | 1 | |
| intravenous methylprednisolone | — | — | — | — | — | 1 | |
| bevacizumab and atezolizumab | — | — | — | — | — | 1 | |
| Atezolizumab plus Bevacizumab | — | — | — | — | — | 1 | |
| Hypotensive Drugs | — | — | — | — | — | 1 | |
| Ofatumumab | — | — | — | — | — | 1 |
Next readouts
- 2016-06
- 2024-06-01
- 2024-10-01
- 2024-12-31
- 2024-12-31
- 2025-12-31
- 2026-03-30
- 2026-06
- 2026-12-01
- 2026-12-13
Top conditions
- Chronic Hepatitis B12
- Acute-On-Chronic Liver Failure10
- Hepatitis B9
- Hepatitis B, Chronic7
- Hepatocellular Carcinoma7
- Chronic Hepatitis b6
- Liver Failure6
- Chronic Hepatitis C5
Frequently asked questions about Third Affiliated Hospital, Sun Yat-Sen University
- How many clinical trials does Third Affiliated Hospital, Sun Yat-Sen University have on ClinicalTrials.gov?
- Third Affiliated Hospital, Sun Yat-Sen University is listed as the lead sponsor on 130 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Third Affiliated Hospital, Sun Yat-Sen University's trials are in Phase 3?
- 5 of Third Affiliated Hospital, Sun Yat-Sen University's trials are in Phase 3, spread across 28 active drug programs.
- What therapeutic areas does Third Affiliated Hospital, Sun Yat-Sen University focus on?
- Third Affiliated Hospital, Sun Yat-Sen University's most-studied conditions on ClinicalTrials.gov are Chronic Hepatitis B, Acute-On-Chronic Liver Failure, Hepatitis B, Hepatitis B, Chronic, Hepatocellular Carcinoma.
- When are Third Affiliated Hospital, Sun Yat-Sen University's next clinical trial readouts?
- Third Affiliated Hospital, Sun Yat-Sen University has 10 upcoming primary-completion readouts tracked here; the soonest is “Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma”, expected around 2016-06.